Tier 2 — strong

Effect of quercetin on the plasma and intracellular concentrations of saquinavir in healthy adults

Robert DiCenzo, Valerie Frerichs, Panupong Larppanichpoonphol, Lisa Predko, Amy Chen, Richard Reichman, Marilyn Morris
Pharmacotherapy 2006 26(9):1255

Bibliography

PubMed
PMID 16945047
DOI
10.1592/phco.26.9.1255
Funding
Indexed grant support: 5M01-RR 00044 — NCRR NIH HHS — United States. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignProspective human pharmacokinetic interaction study
ModelHuman intervention research
Sample10 healthy adults; intracellular analysis available in fewer participants
InterventionSaquinavir 1,200 mg three times daily; quercetin 500 mg three times daily added on days 4–11
Duration11 days
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2006, this source examined safety, interactions and special populations. Design: Prospective human pharmacokinetic interaction study. Sample/model: 10 healthy adults; intracellular analysis available in fewer participants. The exposure or intervention was Saquinavir 1,200 mg three times daily; quercetin 500 mg three times daily added on days 4–11. Follow-up or treatment period: 11 days.

Average plasma saquinavir exposure did not change substantially; intracellular concentrations were highly variable.

Small sample and wide confidence intervals limit exclusion of clinically relevant effects. The study does not establish universal interaction safety.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Interactions: Medicines, Evidence and Precautions. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Average plasma saquinavir exposure did not change substantially; intracellular concentrations were highly variable.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Saquinavir 1,200 mg three times daily; quercetin 500 mg three times daily added on days 4–11; 11 days.

What this study can and cannot tell us

  • Small sample and wide confidence intervals limit exclusion of clinically relevant effects. The study does not establish universal interaction safety.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Parinda A Mehta et al. · Blood advances · 2025
Tier 2
Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
Meilan K Han et al. · BMJ open respiratory research · 2020
Tier 2
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin
Antonella Riva et al. · Minerva cardioangiologica · 2019

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology